Want to see IN:THYROCARE full AI Analyst Report?
THYROCARE Stock Chart & Stats
₹605.25
₹19.80(3.51%)
At close: 4:00 PM EDT
₹605.25
₹19.80(3.51%)
Day’s Range― - ―
52-Week Range₹342.55 - ₹662.00
Previous CloseN/A
Volume3.96M
Average Volume (3M)136.20K
Market Cap
₹89.12B
Enterprise Value₹53.87K
Total Cash (Recent Filing)₹1.90B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)32.4
Beta0.58
Next Earnings
Nov 09, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.68%
Share Statistics
EPS (TTM)17.15
Shares Outstanding159,165,310
10 Day Avg. Volume13,805
30 Day Avg. Volume136,197
Financial Highlights & Ratios
PEG Ratio-0.84
Price to Book (P/B)9.48
Price to Sales (P/S)6.69
P/FCF Ratio28.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)13.27
Revenue Forecast (FY)₹9.92B
Bulls Say, Bears Say
Bulls Say
Low Leverage And Improving ReturnsA very low debt burden gives Thyrocare financial flexibility and limits interest-related pressure on earnings. The sharp improvement in ROE also indicates that the company is deploying its equity base more productively, supporting durable profitability and funding capacity.
Strong Cash GenerationStrong conversion of reported earnings into operating and free cash flow improves the quality of Thyrocare’s profits. This supports reinvestment, shareholder returns, and resilience through changing demand, while reducing reliance on external financing for ongoing needs.
Reaccelerating Growth And ProfitabilityThe return to stronger revenue growth alongside improved net margins suggests renewed operating momentum in the diagnostic services business. If maintained, this combination can expand internal cash generation and strengthen the company’s ability to invest in its testing platform and market reach.
Bears Say
Profitability VolatilityLarge historical margin swings make the current profitability level less predictable over the next several quarters. This uncertainty can limit confidence in earnings durability, because revenue growth may not translate consistently into operating and net income expansion.
Debt Increased ModestlyAlthough leverage remains conservative, the year-over-year increase in debt represents a modest move toward greater balance-sheet usage. Continued borrowing could gradually reduce financial flexibility or add funding costs if the company expands leverage faster than earnings and cash flow.
Uneven Free Cash Flow GrowthThe latest free cash flow surge is encouraging, but earlier declines show that cash expansion has not been consistently linear. Uneven cash growth can make the pace of reinvestment and shareholder distributions less predictable, even when overall cash conversion remains strong.
Thyrocare Technologies Ltd News
THYROCARE FAQ
What was Thyrocare Technologies Ltd’s price range in the past 12 months?
Thyrocare Technologies Ltd lowest stock price was ₹342.55 and its highest was ₹662.00 in the past 12 months.
What is Thyrocare Technologies Ltd’s market cap?
Thyrocare Technologies Ltd’s market cap is ₹89.12B.
When is Thyrocare Technologies Ltd’s upcoming earnings report date?
Thyrocare Technologies Ltd’s upcoming earnings report date is Nov 09, 2026 which is in 51 days.
How were Thyrocare Technologies Ltd’s earnings last quarter?
Thyrocare Technologies Ltd released its earnings results on Jul 23, 2026. The company reported ₹3.3 earnings per share for the quarter, missing the consensus estimate of ₹6.633 by -₹3.333.
Is Thyrocare Technologies Ltd overvalued?
According to Wall Street analysts Thyrocare Technologies Ltd’s price is currently Overvalued.
Does Thyrocare Technologies Ltd pay dividends?
Thyrocare Technologies Ltd pays a Semiannually dividend of ₹7 which represents an annual dividend yield of 1.68%. See more information on Thyrocare Technologies Ltd dividends here
What is Thyrocare Technologies Ltd’s EPS estimate?
Thyrocare Technologies Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Thyrocare Technologies Ltd have?
Thyrocare Technologies Ltd has 159,165,310 shares outstanding.
What happened to Thyrocare Technologies Ltd’s price movement after its last earnings report?
Thyrocare Technologies Ltd reported an EPS of ₹3.3 in its last earnings report, missing expectations of ₹6.633. Following the earnings report the stock price went down -2.301%.
Which hedge fund is a major shareholder of Thyrocare Technologies Ltd?
Currently, no hedge funds are holding shares in IN:THYROCARE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Thyrocare Technologies Ltd
Thyrocare Technologies Limited, an Indian enterprise, delivers a comprehensive array of diagnostic testing solutions to individual patients, medical laboratories, and healthcare providers throughout the nation. Its operations are structured across three main segments: Diagnostic Testing Services, Imaging Services, and other miscellaneous endeavors. The company's primary focus involves conducting numerous medical diagnostic analyses and specialized test panels aimed at the timely detection and effective management of various health conditions. These include, among others, disorders related to the thyroid, growth, metabolism, autoimmune responses, diabetes, anemia, cardiovascular health, infertility, COVID-19, and a broad spectrum of infectious diseases. Under its "Aarogyam" brand, Thyrocare offers 34 distinct profiles of tests, providing patients with extensive wellness and preventative health check-ups. Furthermore, the company sells "Sugarscan" branded glucometers and glucostrips, along with various consumable products and radiopharmaceuticals. Founded in 1996, Thyrocare Technologies Limited is headquartered in Navi Mumbai, India, and functions as a subsidiary of Docon Technologies Private Limited.
Technical Analysis
Krsnaa Diagnostics Limited
―
Dr. Lal PathLabs Limited
―
Metropolis Healthcare Ltd.
―
Vijaya Diagnostic Centre Ltd.
―
Vimta Labs Limited
―